Document Detail


High-dose ketoconazole to untreated stage D prostate cancer.
MedLine Citation:
PMID:  3383945     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Eleven previously untreated patients with stage D prostate cancer were treated with ketoconazole in a dosage of 400 mg p.o. every 8 h. s-Testosterone was used as a measure of antiandrogen effect. Nine patients had a reduction in s-testosterone to castrate levels (less than 2.9 nmol/l) within 3 days. In the remaining two patients, dose escalation of ketoconazole to 400 mg every 6 h did not lead to sufficient reduction in s-testosterone. Two patients had a complete response and four patients had a partial response of 6/11. Additionally, two patients had bone pain relief without normalization of acid phosphatase. Side-effects and adverse reactions were prominent, causing discontinuation of the treatment in nine patients. It is concluded that high-dose ketoconazole is effective in disseminated prostate cancer, but the high frequency of side-effects makes it less attractive than conventional hormone manipulations like castration or estrogens.
Authors:
K Aabo; M Kjaer; H H Hansen
Related Documents :
9052465 - Early experience with high-intensity focused ultrasound for the treatment of benign pro...
2618815 - Creatine-kinase-bb after severe head-injury as an index of prognosis in relation to nat...
7238235 - Anomalous creatine kinase isoenzymes in serum from patients with rectal carcinoma.
1173645 - Elevated carcinoembryonic antigen levels and biliary tract obstruction.
8175225 - Left ventricular performance in patients with normal coronary arteries: hemodynamic cha...
21975205 - Hypereosinophilia in patients with multiple sclerosis treated with natalizumab.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  European journal of cancer & clinical oncology     Volume:  24     ISSN:  0277-5379     ISO Abbreviation:  Eur J Cancer Clin Oncol     Publication Date:  1988 Mar 
Date Detail:
Created Date:  1988-08-05     Completed Date:  1988-08-05     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  8112045     Medline TA:  Eur J Cancer Clin Oncol     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  431-7     Citation Subset:  IM    
Affiliation:
Department of Oncology B, Finsen Institute, Copenhagen, Denmark.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acid Phosphatase / blood
Adult
Aged
Humans
Hydrocortisone / blood
Ketoconazole / administration & dosage*,  adverse effects,  therapeutic use
Male
Middle Aged
Prostatic Neoplasms / blood,  drug therapy*,  radiography
Testosterone / blood
Tomography, X-Ray Computed
Chemical
Reg. No./Substance:
50-23-7/Hydrocortisone; 58-22-0/Testosterone; 65277-42-1/Ketoconazole; EC 3.1.3.2/Acid Phosphatase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Phase II study of estramustine phosphate (Estracyt) in patients with metastatic melanoma.
Next Document:  Adjuvant systemic treatment and the pattern of recurrences in patients with breast cancer.